SCHEMBL1066013

SCHEMBL1066013

NCc1ccccn1.NCc1ccccn1.[Re]

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH1 P35367 2/20 0.64
SMN1; SMN2 Q16637 3/20 0.50
MAPT P10636 1/20 0.50
LIN28A Q9H9Z2 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
GRIN2D O15399 1/20 0.48
GRIN3B O60391 1/20 0.48
GRIN1 Q05586 1/20 0.48
GRIN2A Q12879 1/20 0.48
GRIN2B Q13224 1/20 0.48
GRIN2C Q14957 1/20 0.48
GRIN3A Q8TCU5 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
MAOA P21397 2/20 0.47
MAOB P27338 2/20 0.47
HRH3 Q9Y5N1 1/20 0.47
LMNA P02545 2/20 0.46
TAAR1 Q96RJ0 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29375684 0.97
SCHEMBL10672099 0.97 HRH1 (0.67) HRH1SMN1; SMN2MAPTLIN28ATDP1
SCHEMBL40328 0.97
Water SCHEMBL4248240 0.95
Hydrochloric Acid SCHEMBL8960759 0.95 HRH1 (0.64) HRH1SMN1; SMN2MAPTLIN28ATDP1
SCHEMBL30952386 0.95 HRH1 (0.64) HRH1SMN1; SMN2MAPTLIN28ATDP1
Phosphine SCHEMBL15768023 0.95
Hydrochloric Acid SCHEMBL637197 0.95
SCHEMBL10695677 0.95
Ammonia Solution, Strong SCHEMBL17926734 0.95

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2963017-A1 TECHNETIUM-DIPYRIDINE COMPLEXES, AND METHODS OF USE THEREOF Molecular Insight Pharmaceuticals, Inc. (US) 2016-01-06 EP disclosed
EP-1482985-B1 TECHNETIUM-DIPYRIDINE COMPLEXES, AND METHODS OF USE THEREOF MOLECULAR INSIGHT PHARM INC (US) 2015-12-23 EP disclosed
US-20110229410-A1 TECHNETIUM-DIPYRIDINE COMPLEXES, AND METHODS OF USE THEREOF MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2011-09-22 US disclosed
US-7875258-B2 For use as radiopharmaceuticals; solid phase synthesis; conjugation with DNA and G-protein-coupled receptors; high binding affinity, high labeling yield, superior retention and versatility; labeling without the need for co-ligands; simplification MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2011-01-25 US disclosed
US-20100303725-A1 Technetium- and Rhenium-Bis(heteroaryl) Complexes, and Methods of Use Thereof MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2010-12-02 US disclosed
US-7824661-B2 Technetium- and rhenium-bis(heteroaryl) complexes, and methods of use thereof MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2010-11-02 US disclosed
EP-1713515-A4 TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES, AND METHODS OF USE THEREOF MOLECULAR INSIGHT PHARM INC (US) 2009-07-22 EP disclosed
EP-1718342-A4 TECHNETIUM-AND RHENIUM-BIS(HETEROARYL) COMPLEXES, AND METHODS OF USE THEREOF MOLECULAR INSIGHT PHARM INC (US) 2009-07-22 EP disclosed
US-20090148382-A1 Technetium- and rhenium-bis(heteroaryl) complexes, and methods of use thereof MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2009-06-11 US disclosed
US-20090023787-A1 TECHNETIUM-DIPYRIDINE COMPLEXES, AND METHODS OF USE THEREOF MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2009-01-22 US disclosed
EP-1718342-A1 TECHNETIUM-AND RHENIUM-BIS(HETEROARYL) COMPLEXES, AND METHODS OF USE THEREOF Molecular Insight Pharmaceuticals, Inc. (US) 2006-11-08 EP disclosed
EP-1713515-A1 TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES, AND METHODS OF USE THEREOF Molecular Insight Pharmaceuticals, Inc. (US) 2006-10-25 EP disclosed
EP-1482985-A4 TECHNETIUM-DIPYRIDINE COMPLEXES, AND METHODS OF USE THEREOF MOLECULAR INSIGHT PHARM INC (US) 2006-06-28 EP disclosed
US-20060093552-A1 Technetium-and rhenium-bis(heteroaryl) complexes, and methods of use thereof MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2006-05-04 US disclosed
US-20060034758-A1 Technetium- and rhenium-bis(heteroaryl) complexes, and methods of use thereof MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2006-02-16 US disclosed
WO-2005079865-A1 TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES, AND METHODS OF USE THEREOF MOLECULAR INSIGHT PHARMACEUTICALS (US) 2005-09-01 WO disclosed
WO-2005079866-A1 TECHNETIUM-AND RHENIUM-BIS(HETEROARYL) COMPLEXES, AND METHODS OF USE THEREOF MOLECULAR INSIGHT PHARMACEUTICALS (US) 2005-09-01 WO disclosed
EP-1482985-A2 TECHNETIUM-DIPYRIDINE COMPLEXES, AND METHODS OF USE THEREOF Biostream, Inc. (US) 2004-12-08 EP disclosed
US-20030235843-A1 Technetium-depyridine complexes, and methods of use thereof CITIZENS BANK, N.A. 2003-12-25 US disclosed
WO-2003077727-A2 TECHNETIUM-DIPYRIDINE COMPLEXES, AND METHODS OF USE THEREOF BIOSTREAM, INC. (US) 2003-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060093552-A1 Technetium-and rhenium-bis(heteroaryl) complexes, and methods of use thereof SLC7A5, QPCT, RAB35 HRH1 214/4885SMN1; SMN2 4625/4885MAPT 2543/4885
US-20110229410-A1 TECHNETIUM-DIPYRIDINE COMPLEXES, AND METHODS OF USE THEREOF SLC7A5, SLC7A1, AADAT HRH1 647/4885SMN1; SMN2 4102/4885MAPT 2979/4885
US-20030235843-A1 Technetium-depyridine complexes, and methods of use thereof SLC7A5, DNPEP, SLC7A1 HRH1 1283/4885SMN1; SMN2 4210/4885MAPT 2801/4885
US-20100303725-A1 Technetium- and Rhenium-Bis(heteroaryl) Complexes, and Methods of Use Thereof SLC7A5, RAB35, AADAT HRH1 333/4885SMN1; SMN2 4259/4885MAPT 3876/4885
US-20060034758-A1 Technetium- and rhenium-bis(heteroaryl) complexes, and methods of use thereof SLC7A5, RAB35, AADAT HRH1 333/4885SMN1; SMN2 4259/4885MAPT 3876/4885
US-20090148382-A1 Technetium- and rhenium-bis(heteroaryl) complexes, and methods of use thereof QPCT, SLC7A5, RAB35 HRH1 112/4885SMN1; SMN2 4750/4885MAPT 2926/4885
US-20090023787-A1 TECHNETIUM-DIPYRIDINE COMPLEXES, AND METHODS OF USE THEREOF SLC7A5, SLC7A1, AADAT HRH1 647/4885SMN1; SMN2 4102/4885MAPT 2979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.